Publications
Dynamic Treatment Regimes: Statistical Methods for Precision Medicine In Chapman & Hall/CRC Monographs on Statistics and Applied Probability. Boca Raton: Chapman and Hall/CRC, 2019.
Missing data methods: A semiparametric perspective. In Handbook of Missing Data Methodology. Boca Raton: Chapman and Hall/CRC, 2014.
Bayesian frailty models for multi-state survival data." In Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. New York: Springer, 2016.
"Dynamic spatial pattern recognition in count data." In New Developments in Statistical Modeling, Inference and Application, 185-202. New York: Springer, 2016.
"Dynamic treatment regimes." In Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis. Boca Raton: Chapman & Hall / CRC Press, 2016.
"Research methods for clinical trials in personalized medicine: A systematic review." In Lost In Translation: Barriers to Incentives for Translational Research in Medical Sciences. Singapore: World Scientific, 2014.
"Value search estimators for optimal dynamic treatment regimes." In Adaptive Treatment Strategies in Practice: Planning Trials and Analyzing Data for Personalized Medicine, 135-155. Philadelphia: ASA-SIAM, 2016.
"The analysis of multivariate longitudinal data: a review." Stat Methods Med Res 23, no. 1 (2014): 42-59.
"Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia." Ann Oncol 30, no. 4 (2019): 542-550.
"Ascertaining properties of weighting in the estimation of optimal treatment regimes under monotone missingness." Stat Med 39, no. 25 (2020): 3503-3520.
"Assessing covariate effects using Jeffreys-type prior in the Cox model in the presence of a monotone partial likelihood." J Stat Theory Pract 12, no. 1 (2018): 23-41.
"Assessing temporal agreement between central and local progression-free survival times." Stat Med 34, no. 5 (2015): 844-58.
"Assessing the causal effect of organ transplantation on the distribution of residual lifetime." Biometrics 69, no. 4 (2013): 820-9.
"Auxiliary marker-assisted classification in the absence of class identifiers." J Am Stat Assoc 108, no. 502 (2013): 553-565.
"Bayesian Design of Non-Inferiority Clinical Trials via the Bayes Factor." Stat Biosci 10, no. 2 (2018): 439-459.
"A Bayesian multi-risks survival (MRS) model in the presence of double censorings." Biometrics 76, no. 4 (2020): 1297-1309.
"A Bayesian multi-risks survival (MRS) model in the presence of double censorings." Biometrics 76, no. 4 (2020): 1297-1309.
"Bayesian path specific frailty models for multi-state survival data with applications." Biometrics 71, no. 3 (2015): 760-71.
"Bayesian Transformation Models for Multivariate Survival Data." Scand Stat Theory Appl 41, no. 1 (2014): 187-199.
"bcSeq: an R package for fast sequence mapping in high-throughput shRNA and CRISPR screens." Bioinformatics 34, no. 20 (2018): 3581-3583.
"Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
"Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
"Combining Multiple Observational Data Sources to Estimate Causal Effects." J Am Stat Assoc 115, no. 531 (2020): 1540-1554.
"A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supp." Oncologist 21, no. 7 (2016): 789-94.
"Confident difference criterion: a new Bayesian differentially expressed gene selection algorithm with applications." BMC Bioinformatics 16 (2015): 245.
"A counterfactual p-value approach for benefit-risk assessment in clinical trials." J Biopharm Stat 25, no. 3 (2015): 508-24.
"Discussion of "Combining biomarkers to optimize patient treatment recommendation"." Biometrics 70, no. 3 (2014): 707-10.
"Discussion of "Connections Between Survey Calibration Estimators and Semiparametric Models for Incomplete Data" by T. Lumley, P.A. Shaw & J.Y. Dai." Int Stat Rev 79, no. 2 (2011): 221-223.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
"Dynamic treatment regimes, past, present, and future: A conversation with experts." Stat Methods Med Res 26, no. 4 (2017): 1605-1610.
"Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed." Lifetime Data Anal 19, no. 4 (2013): 513-46.
"Efficient methods for signal detection from correlated adverse events in clinical trials." Biometrics 75, no. 3 (2019): 1000-1008.
"Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data." Biometrics 69, no. 4 (2013): 840-9.
"Estimating effect of environmental contaminants on women's subfecundity for the MoBa study data with an outcome-dependent sampling scheme." Biostatistics 15, no. 4 (2014): 636-50.
"Estimating individualized treatment regimes from crossover designs." Biometrics 76, no. 3 (2020): 778-788.
"Estimating Optimal Treatment Regimes from a Classification Perspective." Stat 1, no. 1 (2012): 103-114.
"Estimation After a Group Sequential Trial." Stat Biosci 7, no. 2 (2015): 187-205.
"On Estimation of Optimal Treatment Regimes For Maximizing -Year Survival Probability." J R Stat Soc Series B Stat Methodol 79, no. 4 (2017): 1165-1185.
"FEATURE ELIMINATION IN KERNEL MACHINES IN MODERATELY HIGH DIMENSIONS." Ann Stat 47, no. 1 (2019): 497-526.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic variation determines VEGF-A plasma levels in cancer patients." Sci Rep 8, no. 1 (2018): 16332.
"Genome analysis and pleiotropy assessment using causal networks with loss of function mutation and metabolomics." BMC Genomics 20, no. 1 (2019): 395.
"Improved doubly robust estimation when data are monotonely coarsened, with application to longitudinal studies with dropout." Biometrics 67, no. 2 (2011): 536-45.
"Incorporating higher-order representative features improves prediction in network-based cancer prognosis analysis." BMC Med Genomics 4 (2011): 5.
"Incorporating Patient Preferences into Estimation of Optimal Individualized Treatment Rules." Biometrics 74, no. 1 (2018): 18-26.
"Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial." Biostatistics 12, no. 2 (2011): 258-69.
"Interpretable Dynamic Treatment Regimes." J Am Stat Assoc 113, no. 524 (2018): 1541-1549.
"Longitudinal dynamic functional regression." J R Stat Soc Ser C Appl Stat 69, no. 1 (2020): 25-46.
"Mixed model analysis of censored longitudinal data with flexible random-effects density." Biostatistics 13, no. 1 (2012): 61-73.
"Moment Adjusted Imputation for Multivariate Measurement Error Data with Applications to Logistic Regression." Comput Stat Data Anal 67 (2013): 15-24.
"A moment-adjusted imputation method for measurement error models." Biometrics 67, no. 4 (2011): 1461-70.
"Multisensory Logic of Infant-Directed Aggression by Males." Cell 175, no. 7 (2018): 1827-1841.e17.
"Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
"Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
"Nomenclature for alleles of the thiopurine methyltransferase gene." Pharmacogenet Genomics 23, no. 4 (2013): 242-8.
"Observation weights unlock bulk RNA-seq tools for zero inflation and single-cell applications." Genome Biol 19, no. 1 (2018): 24.
"Optimal treatment allocations in space and time for on-line control of an emerging infectious disease." J R Stat Soc Ser C Appl Stat 67, no. 4 (2018): 743-770.
"Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data." Biometrics 74, no. 4 (2018): 1180-1192.
"Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART." Contemp Clin Trials 57 (2017): 51-57.
"Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART." Contemp Clin Trials 57 (2017): 51-57.
"Pattern mixture models for clinical validation of biomarkers in the presence of missing data." Stat Med 36, no. 19 (2017): 2994-3004.
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"A Powerful Test for SNP Effects on Multivariate Binary Outcomes using Kernel Machine Regression." Stat Biosci 10, no. 1 (2018): 117-138.
"Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data." J Alzheimers Dis 46, no. 3 (2015): 695-702.
"Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"Properties of Estimators in Exponential Family Settings with Observation-based Stopping Rules." J Biom Biostat 7, no. 1 (2016).
"Proportional hazards model with a change point for clustered event data." Biometrics 73, no. 3 (2017): 835-845.
"Q- and A-learning Methods for Estimating Optimal Dynamic Treatment Regimes." Stat Sci 29, no. 4 (2014): 640-661.
"Quantifying center of pressure variability in chondrodystrophoid dogs." Vet J 226 (2017): 26-31.
"Quantifying center of pressure variability in chondrodystrophoid dogs." Vet J 226 (2017): 26-31.
"On random sample size, ignorability, ancillarity, completeness, separability, and degeneracy: sequential trials, random sample sizes, and missing data." Stat Methods Med Res 23, no. 1 (2014): 11-41.
"Rare Variants Association Analysis in Large-Scale Sequencing Studies at the Single Locus Level." PLoS Comput Biol 12, no. 6 (2016): e1004993.
"Recent progresses in outcome-dependent sampling with failure time data." Lifetime Data Anal 23, no. 1 (2017): 57-82.
"Response to reader reaction." Biometrics 71, no. 1 (2015): 267-273.
"Robust estimation of optimal dynamic treatment regimes for sequential treatment decisions." Biometrika 100, no. 3 (2013).
"A robust method for estimating optimal treatment regimes." Biometrics 68, no. 4 (2012): 1010-8.
"Semiparametric Bayes local additive models for longitudinal data." Stat Biosci 7, no. 1 (2015): 90-107.
"Semiparametric Bayesian local functional models for diffusion tensor tract statistics." Neuroimage 63, no. 1 (2012): 460-74.
"Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
"SNP_NLMM: A SAS Macro to Implement a Flexible Random Effects Density for Generalized Linear and Nonlinear Mixed Models." J Stat Softw 56 (2014): 2.
"Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects." J Biopharm Stat 27, no. 6 (2017): 933-944.
"On the substructure controls in rare variant analysis: Principal components or variance components?" Genet Epidemiol 42, no. 3 (2018): 276-287.
"Superiority of combining two independent trials in interim futility analysis." Stat Methods Med Res 29, no. 2 (2020): 522-540.
"Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
"Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
"Ten Simple Rules for Effective Statistical Practice." PLoS Comput Biol 12, no. 6 (2016): e1004961.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Two-stage design for phase II oncology trials with relaxed futility stopping." Stat Interface 9, no. 1 (2016): 93-98.
"Using decision lists to construct interpretable and parsimonious treatment regimes." Biometrics 71, no. 4 (2015): 895-904.
"Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy." Stat Med 35, no. 8 (2016): 1245-56.
"Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials." Stat Med 31, no. 29 (2012): 3789-804.
"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"